Request for Nominations of Voting Members on a Public Advisory Committee; National Mammography Quality Assurance Advisory Committee, 655-656 [2024-31703]
Download as PDF
<![CDATA[
655
Federal Register / Vol. 90, No. 3 / Monday, January 6, 2025 / Notices
TABLE 2—FOOD CONTACT NOTIFICATIONS (FCNS) NO LONGER EFFECTIVE AS OF JANUARY 6, 2025 WITH A COMPLIANCE
DATE OF JUNE 30, 2025
FCN No.
599 ..............
604 ..............
1186 ............
1676 ............
FCS
Copolymer of perfluorohexylethyl methacrylate, 2-N,N-diethylaminoethyl methacrylate, 2-hydroxyethyl methacrylate, and 2,2’-ethylenedioxydiethyl dimethacrylate, acetic acid salt (CAS Reg. No. 863408–20–2) or
malic acid salt (CAS Reg. No. 1225273–44–8).
Copolymer of perfluorohexylethyl methacrylate, 2-N,N-diethylaminoethyl methacrylate, 2-hydroxyethyl methacrylate, and 2,2’-ethylenedioxydiethyl dimethacrylate, acetic acid salt (CAS Reg. No. 863408–20–2) or
malic acid salt (CAS Reg. No. 1225273–44–8).
Butanedioic acid, 2-methylene-, polymer with 2-hydroxyethyl, 2-methyl-2-propenoate, 2-methyl-2-propenoic
acid and 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl 2-methyl-2-propenoate, sodium salt (CAS Reg. No.
1345817–52–8).
2-propenoic acid, 2-methyl-, 2-hydroxyethyl ester, polymer with 2-propenoic acid and 3,3,4,4,5,5,6,6,7,7,8,8,8tridecafluorooctyl 2-methyl-2-propenoate, sodium salt (CAS Reg. No. 1878204–24–0).
To reflect these changes in status of
the affected FCNs, we established an
Inventory of Food Contact Notifications
That are No Longer Effective on FDA’s
website. The Inventory may be viewed
at https://www.hfpappexternal.fda.gov/
scripts/fdcc/index.cfm?set=FCN-nolonger-effective.
We also updated our Inventory of
Effective Food Contact Notifications
accordingly at https://www.hfpapp
external.fda.gov/scripts/fdcc/
index.cfm?set=FCN.
A food additive is deemed unsafe
unless that substance and its use
conform with a regulation issued under
section 409 of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C.
348) or there is an FCN submitted under
section 409(h) of the FD&C Act that is
effective (section 409(a) of the FD&C
Act). An effective FCN is specific only
to the intended use of the substance
prepared by the manufacturer or
supplier identified in the FCN (section
409(h)(1)(C)).
Our determination that an FCN is no
longer effective does not preclude any
manufacturers or suppliers from
submitting a new FCN for the same FCS,
including for the same intended use,
after FDA has determined that an FCN
is no longer effective, unless the
intended use of the FCS is authorized by
a food additive regulation or the subject
of an issued threshold of regulation
exemption, per 21 CFR 170.105(c).
khammond on DSK9W7S144PROD with NOTICES
We have determined under 21 CFR
25.32(m) that this action is of a type that
does not individually or cumulatively
have a significant effect on the human
environment. Therefore, neither an
environmental assessment nor an
environmental impact statement is
required.
III. References
The following references are on
display at the Dockets Management
Staff, (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
19:04 Jan 03, 2025
Jkt 265001
1061, Rockville, MD 20852, 240–402–
7500 and are available for viewing by
interested persons between 9 a.m. and 4
p.m., Monday through Friday; they also
are available electronically at https://
www.regulations.gov. Although FDA has
verified the website addresses in this
document, please note that websites are
subject to change over time.
1. FDA, Market Phase-Out of Grease-Proofing
Substances Containing PFAS,
Commitment Letters from Industry
available at: https://www.fda.gov/food/
process-contaminants-food/marketphase-out-grease-proofing-substancescontaining-pfas.
Dated: December 30, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2024–31692 Filed 1–3–25; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–N–5889]
Request for Nominations of Voting
Members on a Public Advisory
Committee; National Mammography
Quality Assurance Advisory
Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
II. Analysis of Environmental Impact
VerDate Sep<11>2014
Manufacturer/supplier
Notice.
The Food and Drug
Administration (FDA) is requesting
nominations for voting members to
serve on the National Mammography
Quality Assurance Advisory Committee
in the Center for Devices and
Radiological Health. Nominations will
be accepted for current and upcoming
vacancies effective February 1, 2025,
with this notice. FDA seeks to include
the views of women and men, members
of all racial and ethnic groups, and
individuals with and without
disabilities on its advisory committees
SUMMARY:
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Asahi Glass Co., Ltd. (Manufacturer)
and AGC Chemicals Americas, Incorporated.
Asahi Glass Co., Ltd. (Manufacturer)
and AGC Chemicals Americas, Incorporated.
Asahi Glass Co., Ltd.
AGC Chemicals Americas, Inc.
Asahi Glass Co., Ltd.
AGC Chemicals Americas, Inc.
and, therefore, encourages nominations
of appropriately qualified candidates
from these groups.
DATES: Nominations received on or
before March 7, 2025, will be given first
consideration for membership on the
National Mammography Quality
Assurance Advisory Committee.
Nominations received after March 7,
2025, will be considered for nomination
to the committee as later vacancies
occur.
ADDRESSES: All nominations for
membership should be submitted
electronically by logging into the FDA
Advisory Nomination Portal at https://
www.accessdata.fda.gov/scripts/
FACTRSPortal/FACTRS/index.cfm or by
mail to Advisory Committee Oversight
and Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5103, Silver Spring,
MD 20993–0002. Information about
becoming a member on an FDA advisory
committee can also be obtained by
visiting FDA’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
FOR FURTHER INFORMATION CONTACT:
Regarding all nomination questions for
membership: James P. Swink, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5211,
Silver Spring, MD 20993, 301–796–
6313, James.Swink@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations for voting
members to fill upcoming vacancies on
the National Mammography Quality
Assurance Advisory Committee.
I. General Description of the Committee
Duties
The National Mammography Quality
Assurance Advisory Committee advises
the Commissioner of Food and Drugs
(the Commissioner) or designee on: (1)
developing appropriate quality
standards and regulations for
mammography facilities; (2) developing
appropriate standards and regulations
E:\FR\FM\06JAN1.SGM
06JAN1
656
Federal Register / Vol. 90, No. 3 / Monday, January 6, 2025 / Notices
for bodies accrediting mammography
facilities under this program; (3)
developing regulations with respect to
sanctions; (4) developing procedures for
monitoring compliance with standards;
(5) establishing a mechanism to
investigate consumer complaints; (6)
reporting new developments concerning
breast imaging that should be
considered in the oversight of
mammography facilities; (7)
determining whether there exists a
shortage of mammography facilities in
rural and health professional shortage
areas and determining the effects of
personnel on access to the services of
such facilities in such areas; (8)
determining whether there will exist a
sufficient number of medical physicists
after October 1, 1999; and (9)
determining the costs and benefits of
compliance with these requirements.
II. Criteria for Voting Members
The committee consists of a core of 15
members, including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
physicians, practitioners, and other
health professionals, whose clinical
practice, research specialization, or
professional expertise includes a
significant focus on mammography.
Members will be invited to serve for
overlapping terms of up to 4 years.
Almost all members of this committee
serve as Special Government
Employees.
khammond on DSK9W7S144PROD with NOTICES
III. Nomination Procedures
Any interested person may nominate
one or more qualified persons for
membership on the advisory committee.
Self-nominations are also accepted.
Nominations must include a current,
complete résumé or curriculum vitae for
each nominee, including current
business address, telephone number,
and email address if available, and a
signed copy of the Acknowledgement
and Consent form available at the FDA
Advisory Nomination Portal (see
ADDRESSES). Nominations must specify
the advisory committee for which the
nominee is recommended. Nominations
must also acknowledge that the
nominee is aware of the nomination
unless self-nominated. FDA will ask
potential candidates to provide detailed
information concerning such matters
related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflict of interest.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. 1001 et seq.), and 21 CFR part 14,
relating to advisory committees.
VerDate Sep<11>2014
19:04 Jan 03, 2025
Jkt 265001
Dated: December 30, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2024–31703 Filed 1–3–25; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
National Vaccine Injury Compensation
Program; List of Petitions Received
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
HRSA is publishing this
notice of petitions received under the
National Vaccine Injury Compensation
Program (the Program), as required by
the Public Health Service (PHS) Act, as
amended. While the Secretary of HHS is
named as the respondent in all
proceedings brought by the filing of
petitions for compensation under the
Program, the United States Court of
Federal Claims is charged by statute
with responsibility for considering and
acting upon the petitions.
FOR FURTHER INFORMATION CONTACT: For
information about requirements for
filing petitions, and the Program in
general, contact Lisa L. Reyes, Clerk of
Court, United States Court of Federal
Claims, 717 Madison Place NW,
Washington, DC 20005, (202) 357–6400.
For information on HRSA’s role in the
Program, contact the Director, National
Vaccine Injury Compensation Program,
5600 Fishers Lane, Room 8W–25A,
Rockville, Maryland 20857; (301) 443–
6593, or visit our website at: https://
www.hrsa.gov/vaccinecompensation/
index.html.
SUPPLEMENTARY INFORMATION: The
Program provides a system of no-fault
compensation for certain individuals
who have been injured by specified
childhood vaccines. Subtitle 2 of title
XXI of the PHS Act, 42 U.S.C. 300aa–
10 et seq., provides that those seeking
compensation are to file a petition with
the United States Court of Federal
Claims and to serve a copy of the
petition to the Secretary of HHS, who is
named as the respondent in each
proceeding. The Secretary has delegated
this responsibility under the Program to
HRSA. The Court is directed by statute
to appoint special masters who take
evidence, conduct hearings as
appropriate, and make initial decisions
as to eligibility for, and amount of,
compensation.
SUMMARY:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
A petition may be filed with respect
to injuries, disabilities, illnesses,
conditions, and deaths resulting from
vaccines described in the Vaccine Injury
Table (the Table) set forth at 42 CFR
100.3. This Table lists for each covered
childhood vaccine the conditions that
may lead to compensation and, for each
condition, the time period for
occurrence of the first symptom or
manifestation of onset or of significant
aggravation after vaccine
administration. Compensation may also
be awarded for conditions not listed in
the Table and for conditions that are
manifested outside the time periods
specified in the Table, but only if the
petitioner shows that the condition was
caused by one of the listed vaccines.
Section 2112(b)(2) of the PHS Act, 42
U.S.C. 300aa–12(b)(2), requires that
‘‘[w]ithin 30 days after the Secretary
receives service of any petition filed
under section 2111 the Secretary shall
publish notice of such petition in the
Federal Register.’’ Set forth below is a
list of petitions received by HRSA on
November 1, 2024, through November
30, 2024. This list provides the name of
the petitioner, city, and state of
vaccination (if unknown then the city
and state of the person or attorney filing
the claim), and case number. In cases
where the Court has redacted the name
of a petitioner and/or the case number,
the list reflects such redaction.
Section 2112(b)(2) also provides that
the special master ‘‘shall afford all
interested persons an opportunity to
submit relevant, written information’’
relating to the following:
1. The existence of evidence ‘‘that
there is not a preponderance of the
evidence that the illness, disability,
injury, condition, or death described in
the petition is due to factors unrelated
to the administration of the vaccine
described in the petition,’’ and
2. Any allegation in a petition that the
petitioner either:
a. ‘‘[S]ustained, or had significantly
aggravated, any illness, disability,
injury, or condition not set forth in the
Vaccine Injury Table but which was
caused by’’ one of the vaccines referred
to in the Table, or
b. ‘‘[S]ustained, or had significantly
aggravated, any illness, disability,
injury, or condition set forth in the
Vaccine Injury Table the first symptom
or manifestation of the onset or
significant aggravation of which did not
occur within the time period set forth in
the Table but which was caused by a
vaccine’’ referred to in the Table.
In accordance with section 2112(b)(2),
all interested persons may submit
written information relevant to the
issues described above in the case of the
E:\FR\FM\06JAN1.SGM
06JAN1
]]>Agencies
[Federal Register Volume 90, Number 3 (Monday, January 6, 2025)]
[Notices]
[Pages 655-656]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-31703]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-5889]
Request for Nominations of Voting Members on a Public Advisory
Committee; National Mammography Quality Assurance Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
nominations for voting members to serve on the National Mammography
Quality Assurance Advisory Committee in the Center for Devices and
Radiological Health. Nominations will be accepted for current and
upcoming vacancies effective February 1, 2025, with this notice. FDA
seeks to include the views of women and men, members of all racial and
ethnic groups, and individuals with and without disabilities on its
advisory committees and, therefore, encourages nominations of
appropriately qualified candidates from these groups.
DATES: Nominations received on or before March 7, 2025, will be given
first consideration for membership on the National Mammography Quality
Assurance Advisory Committee. Nominations received after March 7, 2025,
will be considered for nomination to the committee as later vacancies
occur.
ADDRESSES: All nominations for membership should be submitted
electronically by logging into the FDA Advisory Nomination Portal at
https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or
by mail to Advisory Committee Oversight and Management Staff, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103,
Silver Spring, MD 20993-0002. Information about becoming a member on an
FDA advisory committee can also be obtained by visiting FDA's website
at https://www.fda.gov/AdvisoryCommittees/default.htm.
FOR FURTHER INFORMATION CONTACT: Regarding all nomination questions for
membership: James P. Swink, Center for Devices and Radiological Health,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm.
5211, Silver Spring, MD 20993, 301-796-6313, [email protected].
SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting
members to fill upcoming vacancies on the National Mammography Quality
Assurance Advisory Committee.
I. General Description of the Committee Duties
The National Mammography Quality Assurance Advisory Committee
advises the Commissioner of Food and Drugs (the Commissioner) or
designee on: (1) developing appropriate quality standards and
regulations for mammography facilities; (2) developing appropriate
standards and regulations
[[Page 656]]
for bodies accrediting mammography facilities under this program; (3)
developing regulations with respect to sanctions; (4) developing
procedures for monitoring compliance with standards; (5) establishing a
mechanism to investigate consumer complaints; (6) reporting new
developments concerning breast imaging that should be considered in the
oversight of mammography facilities; (7) determining whether there
exists a shortage of mammography facilities in rural and health
professional shortage areas and determining the effects of personnel on
access to the services of such facilities in such areas; (8)
determining whether there will exist a sufficient number of medical
physicists after October 1, 1999; and (9) determining the costs and
benefits of compliance with these requirements.
II. Criteria for Voting Members
The committee consists of a core of 15 members, including the
Chair. Members and the Chair are selected by the Commissioner or
designee from among physicians, practitioners, and other health
professionals, whose clinical practice, research specialization, or
professional expertise includes a significant focus on mammography.
Members will be invited to serve for overlapping terms of up to 4
years. Almost all members of this committee serve as Special Government
Employees.
III. Nomination Procedures
Any interested person may nominate one or more qualified persons
for membership on the advisory committee. Self-nominations are also
accepted. Nominations must include a current, complete
r[eacute]sum[eacute] or curriculum vitae for each nominee, including
current business address, telephone number, and email address if
available, and a signed copy of the Acknowledgement and Consent form
available at the FDA Advisory Nomination Portal (see ADDRESSES).
Nominations must specify the advisory committee for which the nominee
is recommended. Nominations must also acknowledge that the nominee is
aware of the nomination unless self-nominated. FDA will ask potential
candidates to provide detailed information concerning such matters
related to financial holdings, employment, and research grants and/or
contracts to permit evaluation of possible sources of conflict of
interest.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. 1001 et seq.), and 21 CFR part 14, relating to advisory
committees.
Dated: December 30, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2024-31703 Filed 1-3-25; 8:45 am]
BILLING CODE 4164-01-P
